Download App

Log in to access Online Inquiry
Company Overview More
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
CEO: Waggoner Esq., Kenneth L.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > PMCB PharmaCyte Biotech > Detailed Quotes

PMCB PharmaCyte Biotech

2.220-0.050-2.20%
Close 05/20 20:00 ET
High
2.300
Open
2.300
Turnover
90.55K
Low
2.180
Pre Close
2.270
Volume
40.65K
Market Cap
46.00M
P/E(TTM)
Loss
52wk High
9.980
Shares
20.72M
P/E(Static)
Loss
52wk Low
1.790
Float Cap
41.44M
Bid/Ask %
81.82%
Historical High
9.980
Shs Float
18.67M
Volume Ratio
0.33
Historical Low
1.790
Dividend TTM
--
Div Yield TTM
--
P/B
0.50
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.22%
Amplitude
5.29%
Avg Price
2.227
Lot Size
1
Float Cap
41.44M
Bid/Ask %
81.82%
Historical High
9.980
Shs Float
18.67M
Volume Ratio
0.33
Historical Low
1.790
Dividend TTM
--
P/B
0.50
Dividend LFY
--
Turnover Ratio
0.22%
Amplitude
5.29%
Avg Price
2.227
Lot Size
1
Price Forecast

No Data

News

Comment